Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $468.0 million.

  • United Therapeutics' Accounts Payables rose 2860.68% to $468.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $468.0 million, marking a year-over-year increase of 2860.68%. This contributed to the annual value of $344.5 million for FY2024, which is 1560.4% up from last year.
  • Per United Therapeutics' latest filing, its Accounts Payables stood at $468.0 million for Q3 2025, which was up 2860.68% from $432.0 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Accounts Payables registered a high of $468.0 million during Q3 2025, and its lowest value of $165.0 million during Q1 2021.
  • Its 5-year average for Accounts Payables is $280.1 million, with a median of $292.0 million in 2023.
  • As far as peak fluctuations go, United Therapeutics' Accounts Payables tumbled by 663.1% in 2021, and later surged by 5147.66% in 2023.
  • United Therapeutics' Accounts Payables (Quarter) stood at $174.6 million in 2021, then soared by 31.67% to $229.9 million in 2022, then grew by 29.62% to $298.0 million in 2023, then rose by 15.6% to $344.5 million in 2024, then soared by 35.85% to $468.0 million in 2025.
  • Its Accounts Payables stands at $468.0 million for Q3 2025, versus $432.0 million for Q2 2025 and $367.0 million for Q1 2025.